<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932552</url>
  </required_header>
  <id_info>
    <org_study_id>MICTLAN-EXERCISE 1</org_study_id>
    <nct_id>NCT03932552</nct_id>
  </id_info>
  <brief_title>Effects of a Novel Physical Exercise Program in Patients With Cirrhosis (the LFN-exercise Protocol)</brief_title>
  <acronym>LFN-EP</acronym>
  <official_title>Effects of a Physical Exercise Program on Cerebral and Hepatic Hemodynamics in Patients With Cirrhosis. (Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of a structured exercise (The LFN-exercise protocol) program
      plus diet, on cerebral hemodynamics (cerebral blood flow) and hepatic hemodynamics (portal
      pressure), as well as on nutritional status (body composition and nutritional markers) in
      order to facilitate the prescription of exercise in patients with cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Cerebral hemodynamics</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in transcranial Doppler ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in neurocognitive status-1</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in neuropsychometric tests (PHES; psychometric Hepatic encephalopathy score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in neurocognitive status-2</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in neuropsychometric tests (CFF; critical flicker frequency)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hepatic hemodynamics</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in HVPG (HVPG; hepatic venous pressure gradient)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in body composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in body composition (BIA; Bioelectrical impedance analysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in nutritional status</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in blood markers of nutritional status (measured in serum/RNA expression)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical fitness</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in 6MWT (6MWT; Six-minute walk test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in Physical activity Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity tolerance</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in CPET (CPET; Cardiopulmonary exercise test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in markers of systemic oxidative stress</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Personalized nutritional therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerobic exercise + Personalized nutritional therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional therapy</intervention_name>
    <description>individualised nutritional intervention</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis of any aetiology (liver biopsy or a combination of clinical and
             biochemical variables plus evidence of portal hypertension); without decompensation
             during the past month; serum creatinine &lt;1.5 mg/dL; able to attend the appointed
             visits and willing to participate in the study.

        Exclusion Criteria:

          -  Presence of high-risk varices in upper endoscopy (red marks, large varices or gastric
             varices); concomitant cardiopulmonary diseases; decompensated Type 2 Diabetes
             Mellitus, insulin use or proliferative diabetic retinopathy; orthopaedic or
             osteomuscular limitations; any type of cancer, primary sclerosing cholangitis and
             Inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo U Macías-Rodríguez, M.D., PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

